Article
Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation.
Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Apr 2006
Han Sae-Won, Kim Tae-You, Jeon Yoon Kyung, Hwang Pil Gyu, Im Seock-Ah, Lee Kyung-Hun, Kim Jee Hyun, Kim Dong-Wan, Heo Dae Seog, Kim Noe Kyeong, Chung Doo Hyun, Bang Yung-Jue
Abstract excerpt
PURPOSE: Mutations in epidermal growth factor receptor (EGFR) are strongly predictive of gefitinib efficacy in non-small-cell lung cancer. However, the presence of EGFR mutant nonresponses and nonmutant responses points out the need for more comprehensive analysis. PATIENTS AND METHODS: For 69 no...
Topics
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Agents
- Carcinoma, Non-Small-Cell Lung
- DNA Mutational Analysis
- ErbB Receptors
- Female
- Gefitinib
- Gene Dosage
- Genes, ras
- Humans
- In Situ Hybridization